Latest CureVac GmbH Stories
- Boehringer Ingelheim obtains exclusive global rights for development and commercialization of CureVac's investigational therapeutic cancer vaccine CV9202 INGELHEIM and TUBINGEN, Germany,
- Triggered by ongoing and very successful multi-year collaboration TUBINGEN, Germany, July 1, 2014 /PRNewswire/ -- CureVac, a German clinical-stage biopharmaceutical company, today
RNActive® Vaccines Offer Excellent Conditions for Cost-Effective Worldwide Distribution TUBINGEN, Germany and BRUSSELS, March 10, 2014 /PRNewswire/ -- CureVac, a German clinical stage
- A political dynamiter.